Clinical Trial Update: Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule [Phase 3]

View source ↗

Summary

Phase 3 trial assessing long-term immune persistence of GSK's combined Hepatitis A & B vaccine given at 0, 1, 6 months; study completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A
• Hepatitis B

Drugs mentioned

• Combined Hepatitis A/B vaccine (combined hepatitis A and B vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B, Hepatitis A | Phase 3 | Status: COMPLETED | Results posted: 2010-08-26